Ensign Peak Advisors
CRBP icon

Ensign Peak Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

Ensign Peak Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-45,364
Closed -$936K – 1713
2024
Q3 		$936K Hold
45,364
– – ﹤0.01% 1362
2024
Q2 		$2.05M Sell
45,364
-22,136
-33% -$931K ﹤0.01% 894
2024
Q1 		$2.65M Buy
+67,500
New +$1.66M ﹤0.01% 823

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ensign Peak Advisors's CRBP Position: Q4 2024 in Review

Ensign Peak Advisors sold out of Corbus Pharmaceuticals (CRBP) in Q4 2024, closing a stake of 45,364 shares — an estimated $936K sold.

Ensign Peak Advisors first reported a position in CRBP in Q1 2024 and held it in 3 quarters. The position peaked at $2.65M in Q1 2024. 99 funds tracked by Wall St. Rank hold CRBP as of Q4 2024.

  • Ensign Peak Advisors reported no remaining Corbus Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Ensign Peak Advisors sold 45,364 Corbus Pharmaceuticals shares in Q4 2024, an estimated $936K.
  • Ensign Peak Advisors first reported a position in Corbus Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Ensign Peak Advisors's Corbus Pharmaceuticals position peaked at $2.65M in Q1 2024.
  • 99 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2024.

Based on Ensign Peak Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.